DMH International announces FDA approval of their medical imaging software, TouchPACS, created by their subsidiary Touch Medical Solutions.
March 1, 2013 — Coral Springs, Florida — DMH International (OTCBB: DMHI), announced that their wholly-owned subsidiary, Touch Medical Solutions, Inc (TMSI) has received approval from the United States Food and Drug Administration (US-FDA) for their medical imaging software suite, TouchPACS. The software is approved as a Class II medical device.
“The FDA approval has allowed for the immediate marketing of our PACS software,” explained Rik J Deitsch, CEO of DMH International. “TouchPACS is now registered as a Class II medical device and can be sold to hospitals, clinics, radiology centers and physician offices for all of their imaging needs,” he concluded.
TouchPACS is a cutting edge software suite for the PACS medical imaging market (Picture Archiving and Communications Systems). The market was valued at approximately $2.8 billion in 2010 and it is expected to grow to over $5.4 billion by 2017, according to MarketResearch.com, a research firm based out of Rockville, Md.